NZ535684A - Use of a GLP-1 (glucagon like peptide-1) compound to treat gastroparesis by increasing gastric emptying - Google Patents
Use of a GLP-1 (glucagon like peptide-1) compound to treat gastroparesis by increasing gastric emptyingInfo
- Publication number
- NZ535684A NZ535684A NZ535684A NZ53568403A NZ535684A NZ 535684 A NZ535684 A NZ 535684A NZ 535684 A NZ535684 A NZ 535684A NZ 53568403 A NZ53568403 A NZ 53568403A NZ 535684 A NZ535684 A NZ 535684A
- Authority
- NZ
- New Zealand
- Prior art keywords
- glp
- glucagon
- peptide
- gastric emptying
- compound
- Prior art date
Links
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 5
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 title abstract 3
- 206010021518 Impaired gastric emptying Diseases 0.000 title abstract 3
- 102100040918 Pro-glucagon Human genes 0.000 title abstract 3
- 230000030136 gastric emptying Effects 0.000 title abstract 3
- 208000001288 gastroparesis Diseases 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37165002P | 2002-04-10 | 2002-04-10 | |
| PCT/US2003/008457 WO2003087139A2 (en) | 2002-04-10 | 2003-03-27 | Treatment of gastroparesis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ535684A true NZ535684A (en) | 2006-03-31 |
Family
ID=29250714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ535684A NZ535684A (en) | 2002-04-10 | 2003-03-27 | Use of a GLP-1 (glucagon like peptide-1) compound to treat gastroparesis by increasing gastric emptying |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20050164925A1 (OSRAM) |
| EP (1) | EP1496924A4 (OSRAM) |
| JP (1) | JP2005530732A (OSRAM) |
| KR (1) | KR20040098063A (OSRAM) |
| CN (1) | CN1735423A (OSRAM) |
| AU (1) | AU2003220403A1 (OSRAM) |
| BR (1) | BR0308904A (OSRAM) |
| CA (1) | CA2480858A1 (OSRAM) |
| EA (1) | EA200401345A1 (OSRAM) |
| EC (1) | ECSP045345A (OSRAM) |
| HR (1) | HRP20040939A2 (OSRAM) |
| IL (1) | IL164266A0 (OSRAM) |
| MX (1) | MXPA04009929A (OSRAM) |
| NO (1) | NO20044815L (OSRAM) |
| NZ (1) | NZ535684A (OSRAM) |
| PL (1) | PL373658A1 (OSRAM) |
| WO (1) | WO2003087139A2 (OSRAM) |
| ZA (1) | ZA200408111B (OSRAM) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8666495B2 (en) | 1999-03-05 | 2014-03-04 | Metacure Limited | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar |
| US9101765B2 (en) | 1999-03-05 | 2015-08-11 | Metacure Limited | Non-immediate effects of therapy |
| US8792985B2 (en) | 2003-07-21 | 2014-07-29 | Metacure Limited | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar |
| EP1667724A2 (en) | 2003-09-19 | 2006-06-14 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| KR101241862B1 (ko) * | 2003-09-19 | 2013-03-13 | 노보 노르디스크 에이/에스 | 신규 ｇｌｐ-1 유도체 |
| US8612016B2 (en) | 2004-08-18 | 2013-12-17 | Metacure Limited | Monitoring, analysis, and regulation of eating habits |
| US9339190B2 (en) | 2005-02-17 | 2016-05-17 | Metacure Limited | Charger with data transfer capabilities |
| US9821158B2 (en) | 2005-02-17 | 2017-11-21 | Metacure Limited | Non-immediate effects of therapy |
| WO2006097538A1 (en) | 2005-03-18 | 2006-09-21 | Novo Nordisk A/S | Extended glp-1 compounds |
| TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| EP1861160B1 (en) * | 2005-03-24 | 2011-11-16 | Metacure Limited | Wireless leads for gastrointestinal tract applications |
| WO2007080595A2 (en) | 2006-01-12 | 2007-07-19 | Metacure N.V. | Electrode assemblies, tools, and methods for gastric wall implantation |
| WO2006129321A2 (en) | 2005-06-02 | 2006-12-07 | Metacure N.V. | Gi lead implantation |
| US8442841B2 (en) * | 2005-10-20 | 2013-05-14 | Matacure N.V. | Patient selection method for assisting weight loss |
| US8295932B2 (en) | 2005-12-05 | 2012-10-23 | Metacure Limited | Ingestible capsule for appetite regulation |
| CA2800389A1 (en) * | 2006-04-20 | 2007-11-01 | Amgen Inc. | Glp-1 compounds |
| AU2012203915B9 (en) * | 2006-04-20 | 2014-10-09 | Amgen Inc. | GLP-1 compounds |
| WO2008139463A2 (en) * | 2007-05-09 | 2008-11-20 | Metacure Ltd. | Analysis and regulation of food intake |
| US8423130B2 (en) * | 2008-05-09 | 2013-04-16 | Metacure Limited | Optimization of thresholds for eating detection |
| MX2011000847A (es) | 2008-08-06 | 2011-02-25 | Novo Nordisk Healthcare Ag | Proteinas conjugadas con eficacia prolongada in vivo. |
| JP5816097B2 (ja) | 2009-01-22 | 2015-11-18 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 安定な成長ホルモン化合物 |
| US8841249B2 (en) | 2009-08-06 | 2014-09-23 | Novo Nordisk A/S | Growth hormones with prolonged in-vivo efficacy |
| US8642548B2 (en) * | 2009-08-07 | 2014-02-04 | Mannkind Corporation | Val (8) GLP-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome |
| SI2525834T1 (sl) | 2010-01-22 | 2019-10-30 | Novo Nordisk Healthcare Ag | Rastni hormoni s podaljšano in vivo učinkovitostjo |
| AU2011208620B2 (en) | 2010-01-22 | 2015-04-16 | Novo Nordisk Health Care Ag | Stable growth hormone compounds |
| US8934975B2 (en) | 2010-02-01 | 2015-01-13 | Metacure Limited | Gastrointestinal electrical therapy |
| EP2565202A4 (en) | 2010-04-30 | 2013-10-30 | Sanwa Kagaku Kenkyusho Co | PEPTIDE FOR IMPROVING THE IN VIVO STABILITY OF A PHYSIOLOGICALLY ACTIVE SUBSTANCE OR ANALOGUES AND PHYSIOLOGICALLY ACTIVE SUBSTANCE AND ANALOGUES HAVING IN VIVO STABILITY IMPROVEMENT |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| MX362190B (es) | 2012-12-21 | 2019-01-08 | Sanofi Sa | Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon. |
| CN105120887A (zh) | 2013-04-05 | 2015-12-02 | 诺和诺德保健股份有限公司 | 生长激素化合物制剂 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6268343B1 (en) * | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| JP2002510193A (ja) * | 1997-03-31 | 2002-04-02 | イーライ・リリー・アンド・カンパニー | グルカゴン様ペプチド−１類似体 |
| IL142707A0 (en) * | 2000-04-27 | 2002-03-10 | Pfizer Prod Inc | Methods of treating obesity using a neurotensin receptor ligand |
-
2003
- 2003-03-27 EP EP03716707A patent/EP1496924A4/en not_active Withdrawn
- 2003-03-27 EA EA200401345A patent/EA200401345A1/ru unknown
- 2003-03-27 BR BR0308904-5A patent/BR0308904A/pt not_active IP Right Cessation
- 2003-03-27 CN CNA038080079A patent/CN1735423A/zh active Pending
- 2003-03-27 CA CA002480858A patent/CA2480858A1/en not_active Abandoned
- 2003-03-27 MX MXPA04009929A patent/MXPA04009929A/es not_active Application Discontinuation
- 2003-03-27 HR HRP20040939 patent/HRP20040939A2/hr not_active Application Discontinuation
- 2003-03-27 IL IL16426603A patent/IL164266A0/xx unknown
- 2003-03-27 NZ NZ535684A patent/NZ535684A/xx unknown
- 2003-03-27 PL PL03373658A patent/PL373658A1/xx unknown
- 2003-03-27 AU AU2003220403A patent/AU2003220403A1/en not_active Abandoned
- 2003-03-27 US US10/508,762 patent/US20050164925A1/en not_active Abandoned
- 2003-03-27 WO PCT/US2003/008457 patent/WO2003087139A2/en not_active Ceased
- 2003-03-27 KR KR10-2004-7016025A patent/KR20040098063A/ko not_active Ceased
- 2003-03-27 JP JP2003584094A patent/JP2005530732A/ja active Pending
-
2004
- 2004-10-07 ZA ZA200408111A patent/ZA200408111B/xx unknown
- 2004-10-08 EC EC2004005345A patent/ECSP045345A/es unknown
- 2004-11-05 NO NO20044815A patent/NO20044815L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2480858A1 (en) | 2003-10-23 |
| KR20040098063A (ko) | 2004-11-18 |
| JP2005530732A (ja) | 2005-10-13 |
| AU2003220403A1 (en) | 2003-10-27 |
| EA200401345A1 (ru) | 2005-08-25 |
| WO2003087139A3 (en) | 2004-01-08 |
| ECSP045345A (es) | 2006-04-19 |
| ZA200408111B (en) | 2005-10-07 |
| EP1496924A4 (en) | 2007-05-30 |
| HRP20040939A2 (en) | 2004-12-31 |
| CN1735423A (zh) | 2006-02-15 |
| NO20044815L (no) | 2005-01-07 |
| PL373658A1 (en) | 2005-09-05 |
| MXPA04009929A (es) | 2006-03-10 |
| BR0308904A (pt) | 2005-05-03 |
| US20050164925A1 (en) | 2005-07-28 |
| IL164266A0 (en) | 2005-12-18 |
| WO2003087139A2 (en) | 2003-10-23 |
| EP1496924A2 (en) | 2005-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ535684A (en) | Use of a GLP-1 (glucagon like peptide-1) compound to treat gastroparesis by increasing gastric emptying | |
| WO2003018516A3 (en) | Glucagon-like peptide-1 analogs | |
| DE60124710D1 (de) | Analoge des glucagon ähnlichen peptid-1 | |
| MX2008013304A (es) | Compuestos de peptido 1 tipo glucagon. | |
| PT1928499E (pt) | Utilização de um inibidor da dpp-iv para reduzir eventos hipoglicémicos | |
| EP0464022A4 (en) | Insulinotropic hormone | |
| SI1808168T1 (sl) | Kombinacijska terapija za zdravljenje diabetesa in stanj v zvezi z njim ter za zdravljenje stanj, izboljšanih s povečanjem krvnega GLP-1 nivoja | |
| TW200505434A (en) | Therapeutic treatment | |
| WO2003061362A3 (en) | Methods and compositions for treating polycystic ovary syndrome | |
| WO2004002421A3 (en) | Method for the treatment of multiple sclerosis | |
| AU2003203146A1 (en) | Use of glp-1 compound for treatment of critically ill patients | |
| ZA200405342B (en) | The use of melagatran for the manufacture of a medicament for the treatment of type i diabetes mellitus | |
| YU40202A (sh) | Novi derivati tiazolidindiona kao antidijabetički agensi | |
| AU2003239813A1 (en) | Use of pleuromutilins for the treatment of disorders caused by helicobacter pylori | |
| GB0218970D0 (en) | Fragments of Insulin c-peptide | |
| ZA200705470B (en) | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | |
| GB0323979D0 (en) | Therapeutic applications for c-peptide | |
| AU2002319381A1 (en) | Use of antidiabetics for making a medicine with cicatrizing effect | |
| PL372345A1 (en) | Treatment of type i diabetes mellitus using growth hormone antagonist | |
| WO2004105780A3 (en) | Compositions comprising gastrin compounds and their use in diabetes | |
| UA88862C2 (en) | Glucagon-like peptide-1 analogs | |
| AU2011213703B2 (en) | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | |
| AU2003256614A1 (en) | Implantable electrode with flexible region to accommodate micro-movement | |
| TW200507835A (en) | Adamantylglycine-based inhibitors of dipeptidyl peptidase iv and methods | |
| HK1107939A (en) | Combination therapy for the treatment of obesity and diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed |